PETN DESI hearing
PETN DESI hearing: Began Oct. 5 and is scheduled to run through Oct. 25 in room 4-35-A at FDA's Parklawn Building in Rockville, Maryland. Witnesses that will be cross-examined include representatives from Warner-Lambert and Bolar, as well as FDAers and outside experts representing the agency. In 1984, FDA proposed to withdraw the NARDs for single-entity coronary vasodilators containing pentaerythritol tetranitrate, citing the lack of the products efficacy for treating angina.
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.